Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Repligen to $220 from $251 and keeps a Buy rating on the shares following quarterly results. The firm cites near-term headwinds to growth and margins, but notes the base business remains healthy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN: